What drug is ensidipine?

Enasidenib is a targeted treatment for leukemia. It is mainly used to treat relapsed or refractory acute myeloid leukemia (AML) carrying isocitrate dehydrogenase2 (IDH2) mutation. It belongs to the IDH2 inhibitor drug class and exerts a therapeutic effect by interfering with abnormal metabolic pathways and promoting leukemia cell apoptosis.

Ensidipine is an oral drug that interferes with cellular metabolic pathways by specifically inhibiting the abnormal enzyme activity in AML patients carrying IDH2 mutations. IDH2Mutation leads to excessive accumulation of 2-hydroxyglutarate (2-HG), which in turn affects normal cell function and hematopoietic processes. Ensidipine suppresses the proliferation of leukemia cells and promotes apoptosis by inhibiting the activity of IDH2 enzyme, reducing the accumulation of 2-HG and restoring normal metabolic pathways.

Ensidipine is mainly used to treat relapsed or refractory AML carrying IDH2 mutations in adult patients. This IDH2 mutation is a common leukemia genetic variation that affects AML patient outcomes and prognosis. The use of ensidipine provides a new treatment option for patients with this specific subtype of AML.

In clinical trials, ensidipine has shown significant efficacy, able to achieve remission of leukemia cells and significantly extend the progression-free survival of patients. For some patients, ensidipine can even help achieve complete remission (CR), thereby improving survival and quality of life.

Ensidipine is usually taken as an oral medication once daily. The dosage and usage are usually determined based on the patient's specific condition, severity of illness, and tolerance. The doctor will adjust the dosage as needed to achieve the best therapeutic effect.

In general, ensidipine, as a new targeted therapy for AML, provides an effective treatment option for AML patients carrying IDH2 mutations. Its unique mechanism of action and significant efficacy bring new hope to AML patients and make important contributions to further research and development in the field of leukemia treatment.